New Drug Doubles Survival Time for Pancreatic Cancer

For decades, doctors called it "undruggable." Now, a breakthrough treatment is giving hope to thousands of people facing one of cancer's toughest diagnoses.

More than 90% of the most common pancreatic cancer tumors carry a KRAS mutation. For years, scientists knew this genetic flaw drove the disease but couldn't find a way to stop it. That's changed with a new class of drugs called RAS inhibitors, which doubled overall survival time in patients with advanced pancreatic cancer compared to chemotherapy alone.

The Pancreatic Cancer Action Network recently hosted a webinar bringing together leading researchers and patient advocates to discuss what this means for people diagnosed today. Dr. Anna Berkenblit, PanCAN's Chief Scientific and Medical Officer, explained that biomarker testing can now identify which patients have KRAS mutations and could benefit from these targeted treatments.

Terri Conneran, a lung cancer survivor and founder of KRAS Kickers, shared her perspective as someone who's lived with a KRAS-driven cancer. Her advocacy work helped push for the research that made these new treatments possible. She joined oncologists from Moffitt Cancer Center and University of North Carolina at Chapel Hill to explain how patients can access testing and clinical trials.

The timing matters enormously. Pancreatic cancer has been notoriously difficult to treat, with limited options for patients once the disease spreads. These new inhibitors represent the first effective way to directly attack the genetic root of most pancreatic tumors.

The Ripple Effect

This breakthrough extends beyond pancreatic cancer. KRAS mutations appear in many cancer types, including lung and colorectal cancers. The drugs being tested now could help thousands of patients across multiple diagnoses.

PanCAN now helps patients navigate biomarker testing through their Patient Services program. Knowing whether a tumor has a KRAS mutation can open doors to clinical trials and targeted therapies that weren't available even two years ago. Several trials are currently enrolling patients to test combinations that could make these treatments even more effective.

The shift from "undruggable" to double survival time took decades of persistent research. Now that scientists have solved this puzzle, they're applying similar approaches to other genetic targets once considered impossible to reach.

What seemed impossible just a few years ago is now changing the standard of care for one of medicine's toughest challenges.